Outcome of Board Meeting

September 9, 2026 To To Corporate Relationship Department The Manager – Listing BSE Ltd National Stock Exchange of India Ltd Mumbai – 400 001 Mumbai – 400 051 Scrip Code: 524816 Scrip Code: NATCOPHARM Dear Sirs/Madam(s), Sub: Outcome of Board Meeting pursuant to Regulation 30 read with Schedule III of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 In furtherance to the intimation dated August 14, 2026 and pursuant to Regulation 30 read with Schedule III and other applicable provisions of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended (“LODR Regulations”), please be informed that the Board of Directors at their meeting held on Wednesday, September 9, 2026, has inter-alia considered and approved the following: 1. Issuance of fully paid up equity shares of the Company of face value of ₹2 each (“Rights Equity Shares”) for an amount not exceeding ₹1,300 crore (Rupees One Thousand and Three Hundred Crore only) by way of a rights issue to the eligible equity shareholders of the Company, as on the record date (to be determined and notified subsequently), in accordance with applicable laws, including the Securities and Exchange Board of India (Issue of Capital and Disclosure Requirements) Regulations, 2018, as amended (“SEBI ICDR Regulations”), subject to such regulatory and statutory approvals, as may be required under the applicable laws. 2. Constitution of the Fund-Raising Committee of the Board with the following members and delegation of such powers as may be necessary to give effect to the Rights Issue: i. Sri V.C. Nannapaneni, Chairman ii. Sri Rajeev Nannapaneni, Member iii. Sri P.S.R.K. Prasad, Member 3. The Draft Letter of Offer for the Rights Issue, in accordance with the provisions of the Companies Act, 2013, the SEBI (ICDR) Regulations and other applicable laws. 4. Update on the Scheme of Arrangement (Demerger): This is in continuation of our earlier intimation about the scheme of arrangement (Demerger) between Natco Pharma Limited (“Demerged Company” or “Company”) and Natco Crop Health Sciences Limited (“Resulting Company”) and their respective shareholders and creditors under Sections 230 to 232 and other applicable provisions of the Companies Act, 2013 (“Scheme” or “Scheme of Arrangement”). The Scheme was submitted to the Stock Exchanges in accordance with the applicable provisions of Regulation 37 of the SEBI LODR Regulations read with the SEBI Scheme Circular and the Company has received the Observation Letter from both the stock exchanges. The Company has not filed the Scheme and related applications with the Hon’ble National Company Law Tribunal. The fund raising by way of a Rights Issue proposed at the meeting of the board of directors held on September 09, 2026 is expected to result in change to the Company’s capital structure and shareholding pattern and consequently would require necessary changes to the Scheme. Accordingly, the Board at its meeting held on September 09, 2026, has considered and decided to consequentially make necessary changes to the Scheme appropriately post completion of the Rights Issue with a view to, inter alia, maintain the share swap ratio in the revised Scheme the same as the one proposed in the Scheme in respect of which the Company has received the Observation Letters from the Stock Exchanges. The Company proposes to make appropriate filings of such revised Scheme with the Stock Exchanges post completion of the now proposed Rights Issue as aforesaid. The disclosure relating to the rights issue, as required pursuant to Regulation 30 read with Schedule III of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 is attached as per Annexure I. Meeting commenced at 10.35 a.m. and concluded at 11:35 a.m. We request you to take the aforesaid on record. Thanking you, Yours faithfully, For Natco Pharma Limited Ch. Venkat Ramesh Company Secretary & Compliance Officer Encl.: as above Annexure I Disclosure under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 Sl. No. Particulars Details 1 Type of securities proposed to Equity shares of the Company of face value be issued (viz. equity shares, of ₹2 each convertibles, etc.) 2 Type of issuance (further public Rights issue to the eligible equity offering, rights issue, shareholders of the Company, as on the depository receipts record date. (ADR/GDR), qualified institutions placement, The total number of Rights Equity Shares to preferential allotment etc.) be issued will be determined upon finalisation of the issue price and the rights entitlement ratio. 3 Total number of securities Not exceeding ₹ 1,300 crore proposed to be issued or the total amount for which the securities will be issued (approximately) 4 In case of preferential issue the Not Applicable listed entity shall disclose the following additional details to the stock exchange(s) 5 In case of bonus issue the listed Not Applicable entity shall disclose the following additional details to the stock exchange(s) 6 In case of issuance of Not Applicable depository receipts (ADR/GDR) or FCCB the listed entity shall disclose following additional details to the stock exchange(s) 7 In case of issuance of debt Not Applicable securities or other non- convertible securities the listed entity shall disclose following additional details to the stock exchange(s): 8 Any cancellation or termination Not Applicable of proposal for issuance of securities including reasons thereof